KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Other Accumulated Expenses: 2009-2025

Historic Other Accumulated Expenses for Charles River Laboratories International (CRL) over the last 17 years, with Sep 2025 value amounting to $216.0 million.

  • Charles River Laboratories International's Other Accumulated Expenses rose 5.30% to $216.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $216.0 million, marking a year-over-year increase of 5.30%. This contributed to the annual value of $194.0 million for FY2024, which is 4.53% down from last year.
  • Latest data reveals that Charles River Laboratories International reported Other Accumulated Expenses of $216.0 million as of Q3 2025, which was up 4.21% from $207.2 million recorded in Q2 2025.
  • Over the past 5 years, Charles River Laboratories International's Other Accumulated Expenses peaked at $216.0 million during Q3 2025, and registered a low of $97.3 million during Q1 2021.
  • In the last 3 years, Charles River Laboratories International's Other Accumulated Expenses had a median value of $201.7 million in 2023 and averaged $200.8 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first declined by 10.63% in 2021, then spiked by 48.47% in 2022.
  • Charles River Laboratories International's Other Accumulated Expenses (Quarterly) stood at $140.4 million in 2021, then skyrocketed by 45.67% to $204.6 million in 2022, then dropped by 0.67% to $203.2 million in 2023, then fell by 4.53% to $194.0 million in 2024, then increased by 5.30% to $216.0 million in 2025.
  • Its Other Accumulated Expenses was $216.0 million in Q3 2025, compared to $207.2 million in Q2 2025 and $211.5 million in Q1 2025.